Best Infectious Diseases Companies in South Korea
The 79 best Infectious Diseases companies in South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cellid.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in South Korea
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cellid Developer of personalized vaccines to treat cancer and infectious diseases 32Patents top 32%Funding top 35%Innovation top 40%Moat top 45% All 8 signals ▾Patentstop 32% Fundingtop 35% Innovationtop 40% Moattop 45% Marketbottom 48% Globalbottom 35% Fin. healthbottom 35% Techbottom 22% Patents: 32 patents matched (strict assignee match) · 26 filings since 2022 vs 4 in 2017-21 Funding: Raised $2.4B across 1 rounds · 1 rounds over 12 yrs (0.1/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $2.4B | 120 mo ago | Public | — | 2014 | PHPNginxNaver Analytics+5 | 32 patents NK cell-based cancer vaccines and replication-deficient adenoviral vector platforms | — |
| 2 | Lemonex Developer of drug delivery technology and biosensor technology | $27M | 62 mo ago | Series C | Dal-Hee Min Co-Founder & CTO | 2013 | — | 181 patents Nanocarrier-based drug and nucleic‑acid delivery systems for antiviral and cancer therapies | — |
| 3 | Pharmcadd Provider of CAAD based drug discovery platform | $22M | 62 mo ago | Series B | Woo Wook Founder | 2019 | — | 21 patents AI-based protein structure prediction and piperidine-derived drug discovery | — |
| 4 | Microbiotics Developer of small molecule therapeutics for infectious diseases 32Funding top 39%Talent bottom 49%Market bottom 44%Global bottom 29% All 4 signals ▾Fundingtop 39% Talentbottom 49% Marketbottom 44% Globalbottom 29% Funding: Raised $14.3M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 32/100 | $14M | 9 mo ago | Series B | Yong Dong- eun CEO | 2016 | — | — | — |
| 5 | Connext Provider of therapeutic solution for treating orphan diseases 22Funding top 36%Moat top 38%Patents top 49%Innovation bottom 45% All 8 signals ▾Fundingtop 36% Moattop 38% Patentstop 49% Innovationbottom 45% Talentbottom 45% Globalbottom 31% Marketbottom 29% Techbottom 29% Funding: Raised $9.9M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents rank vs industry peers · Fliar Intelligence Index 22/100 | $10M | 3 mo ago | Series C | Woo-Jong Lee CEO & Owner | 2017 | GnuboardMySQLPHP+15 | 9 patents Stabilized collagenase enzyme formulations for biomedical and industrial applications | — |
| 6 | Eubiologics Company providing customized services for development and manufacturing biologics from both mammalian cell… | $8M | 98 mo ago | Public | Yeong Ok Baik CEO | 2012 | — | 34 patents CRM197 carrier protein production and viral subunit vaccine formulations for infectious diseases | — |
| 7 | BioApplications Developer of plant-based vaccines for infectious diseases | $4M | 47 mo ago | Series A | Eun-Ju Sohn CEO | 2011 | — | 153 patents Plant-based recombinant vaccine and therapeutic protein production for animal and human diseases | — |
| 8 | Vaxdigm Developer of vaccines and immunotherapies for infectious disease 14Moat top 38%Patents top 45%Innovation top 50%Funding bottom 41% All 6 signals ▾Moattop 38% Patentstop 45% Innovationtop 50% Fundingbottom 41% Globalbottom 31% Marketbottom 26% Moat: Editorial + unicorn rating 4/10 · IP moat: 13 patents Patents: 13 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 14/100 | $2M | 19 mo ago | Series A | — | 2021 | — | 13 patents Viral nucleocapsid-based platforms for protein expression and self-assembling nanoparticle vaccines | — |
| 9 | Seegene Technologies Developer of molecular diagnostic kits to detect infectious and genetic diseases | $2M | 78 mo ago | Public | Jong Yoon Chun CEO | 2000 | Node.jsSalesforceTailwind CSS+14 | 1,257 patents Multiplex nucleic‑acid diagnostic assay design, automation, and data‑driven infectious disease testing | 1 launch · 1 award |
| 10 | Sonolux Healthtech Provider of an air based virus detection system 29Talent bottom 45%Funding bottom 44%Global bottom 33% All 3 signals ▾Talentbottom 45% Fundingbottom 44% Globalbottom 33% Talent: 1 named leader on record Funding: Raised $358k across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $358K | 19 mo ago | Seed | Seung Song CEO | 2022 | — | — | 1 partnership |
| 11 | Quantamatrix Multiplexed platform for disease daignosis | $198K | 144 mo ago | Public | Sunghoon Kwon Founder & CEO | 2010 | WordPress Block EditorWordPressMySQL+8 | 68 patents Rapid point‑of‑care microbial diagnostics and antibiotic susceptibility testing platforms | — |
Top 12 Infectious Diseases companies in South Korea
#1
Series C · Yeongcheon si, North Gyeongsang Province · founded 2017 · 23 employees$9.9Mraised▾
Provider of therapeutic solution for treating orphan diseases. The company pipeline products are TLR and TLR5 which can be used for agonists in pathogen recognition and activation of innate immunity, pathogen-associated molecular patterns (PAMPs) used for diseases like GvHD, Mucositis, and ARS. Other products offered by the company are Collagenase enzymes derived from microorganisms that break down collagen and used for the treatment of different musculoskeletal diseases like Dupuytren’s contracture, Peyronie’s Disease, Cellulite, and Wound debridement.
- Mar 2026Series C$9.9M
#2
Series B · Seoul, Seoul · founded 2016 · 29 employees$14.3Mraised▾
Developer of small molecule therapeutics for infectious diseases. The company is developing a treatment through bacteriophage for multi-drug resistant bacterias which include Pseudomonas, E.oli, Acinetobacter, and others.
- Sep 2025Series B$14.3M
- Oct 2024Series B—
#3
Public · Seoul, Seoul · founded 2014 · 68 employees$2.4Braised▾
Cellid is involved in developing personalized vaccines for treating cancer and infectious diseases. They have developed a platform, CeliVax, which activates the anti-cancer immune system which allows the immune cells to detect and kill cancer cells. Their pipeline products include BVAC-C is being investigated for cervical, head, and neck cancer, and BVAC-B for gastric cancer. The candidates are in phase II clinical trial.
- 2016Series A—
- 2015Series A—
- 2014Series A—
- 2014Series A—
#4
Series A · Seoul, Seoul · founded 2021 · 9 employees$1.9Mraised▾
Developer of vaccines and immunotherapies for infectious disease. It offers synthetic antigen vaccines using microorganisms and animal cells for rapid protein development and production, DNA vaccine, and mRNA vaccine for covid and viral diseases.
- Oct 2024Series A$1.9M
#5
Seed · Seoul, Seoul · founded 2022$357.5Kraised▾
Provider of an air based virus detection system. It is designed to protect individuals from invisible airborne viruses. It utilizes Photonic PCR technology to amplify air samples and detect viruses. The system offers real time monitoring, and also detect respiratory viruses, including Influenza A, Coronavirus, and RSV.
- Nov 2024Seed$357.5K
#6
Series C · Seoul, Seoul · founded 2013 · 9 employees$27.5Mraised▾
Developer of drug delivery technology and biosensor technology. The DegradaBALLis a drug delivery technology for the development of gene therapy, cancer immunotherapy, antibody therapy, and synthetic drugs. The PANGO technology is the next-generation drug screening technology that allows the rapid screening of antiviral drugs from the drug candidate library.
- Apr 2021Series C$13.9M
- Dec 2018Series B$10.3M
- Mar 2018Series A$3.3M
#7
Series B · Busan, Busan · founded 2019 · 35 employees$22Mraised▾
Provider of CAAD based drug discovery platform. The Pharmulator platform uses AI, network theory, quantum calculation, and molecular dynamics that predict protein structure to design and synthesize new drug candidates. The company is developing drugs for NAOC, cancer, Alzheimers, and covid-19.
- Mar 2021Series B$15.5M
#8
Series A · Pohang, Gyeongsangbuk-do · founded 2011$3.9Mraised▾
Developer of plant-based vaccines for infectious diseases. The company offers HERBAVAC CSF green marker vaccine, a plant-based classical swine fever vaccine. It also engaged in developing vaccines for COVID-19, Zika, and dementia prevention.
- Jul 2022Series A$3.9M
#9
Public · Seoul, Seoul · founded 2012 · 314 employees$7.5Mraised▾
EuBiologics is a Contract Research and Manufacturing Organization (CRMO) providing customized services for mammalian cell and microbial-derived biopharmaceutical from cell line development to GMP production and also developing its own portfolio of products. They specialize in vaccine development and also in the development of advanced biopharmaceuticals. The company also has a pipeline of vaccine products. Euvichol (Oral Cholera Prevention Vaccine) and CRM 197 (immunological transferring protein) have been launched and many others are in various stages of preclinical and clinical development.
- Apr 2018Post IPO$28.1M
- Aug 2014Series A$7.5M
#10
Public · Seoul, Seoul · founded 2000$1.6Mraised▾
Developer of molecular diagnostic kits to detect infectious and genetic diseases. It has developed IVD tests that detect causes of disease by analyzing nucleic acids such as DNA and RNA which contain genetic information. It has IVD reagents including kits for detecting respiratory diseases, gastrointestinal diseases, sexually transmitted diseases (STDs), human papillomavirus (HPV), tuberculosis, sepsis, and meningitis.
- Dec 2019Grant (prize money)$1.6M
#11
Public · Seoul, Seoul · founded 2010 · 113 employees$198Kraised▾
QuantaMatrix is focused on development and commercialization of molecular and cellular diagnostic tools and related disposable kits. The company has developed an immunodiagnostic platform based on their proprietary encoded microdisk technology. The company claims that 1000 multiplex are possible in 1 microwell. The company offers microfluidic chips and automated imaging systems, a direct Rapid Antibiotic Susceptibility Test is a fully automated microscopic imaging tool (4 hours). The available diagnostic tests include an HPV kit and an STD kit for pathogen detection.
- 2014Seed$198K
#12
Seed · Yuseong District, Hoseo · founded 2020—raised▾
Developer of antibiotics against drug-resistant infections. The company is developing bacteriophage-based oral therapeutics targeting H. pylori, endolysin-based IV therapeutics targeting bacteria based on gene recombinant technology, fermentation techniques, and target material separating purifying technology.
- Nov 2025Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Diagnostics is moving in South Korea
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 724 South Korea-affiliated papers.
- Samsung Medical Center66
- Yonsei University66
- Sungkyunkwan University64
- Korea University46
- Asan Medical Center44
- Liquid biopsy5→34
- Point-of-care testing5→27
- Point of care1→20
- Microfluidics2→14
- Nanotechnology1→12
- Liquid biopsy10→100
- Cancer2→33
- Point-of-care testing17→45
- Biomarker3→22
- Nanotechnology2→21
- Liquid biopsy1→13
- Point-of-care testing13→17
- Diagnostic test2→6
- Biopsy1→5
- Malaria4→7
Where diagnostics is researched across South Korea
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing diagnostics patents in South Korea
South Korea diagnostics patent filing is accelerating — 115 filings from 56 assignees (2016–2025), led by Justem, MD HIGH TECH, SD Biosensor; annual filings 1→18.
- Justem14
- MD HIGH TECH13
- SD Biosensor10
- SOL BIO9
- Exopert6
- LG Electronics4
- Genesisego4
- EONE Reference Laboratory4
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.